Research Paper Volume 14, Issue 19 pp 7941—7958
ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer
Figure 2. Correlation analysis of risk factors between model group and validation group. (A) The survival time and survival status of pancreatic cancer patients in the model group as a function of their risk values. (B) The survival time and survival status of pancreatic cancer patients in the validation group as a function of their risk values. (C) Heat map of gene expression as a function of risk values in the model group. (D) Heat map of gene expression as a function of risk values in the validation group.